刘晓东，教授，博士生导师。中国药科大学药学院副院长、中国药理学会数学药理学会理事、中国药理学会药物代谢动力学专业委员会副主任委员、江苏省青蓝工程跨世纪省级学术带头人培养对象和江苏省“333”工程培养对象(第二层次）。2009年度入选江苏高等学校优秀科技创新团队带头人，享受国务院政府特殊津贴。主要研究方向：中药药物代谢动力学、血脑屏障与药物转运、药物相互作用和创新药物的药代动力学研究。主持7项国家自然科学基金项目，主持教育部双语示范课程建设。发表学术论文120余篇，其中SCI论文90篇，获得江苏省科学技术进步一等奖（排2）1 项和国家科学技术进步二等奖（排2）1项。在指导的研究生中1 名博士生获得省优秀博士论文，2名硕士生获得省优秀硕士论文。
招生专业：　药物代谢动力学博士和硕士
近5年代表性论文
1. Li J, Guo HF, Liu C, Zhong ZY, Liu L*, Liu XD*. Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic mode.Clin Pharmacokinet. 2015; 54: 179.
2. Jiang S, Zhao W, Chen Y, Zhong Z, Zhang M, Li F, Xu P, Zhao K, Li Y, Liu L*, Liu X*. Paroxetine decreased plasma exposure of glyburide partly via inhibiting intestinal absorption in ratsDrug Metab Pharmacokinet.2015;30:240
3. Zhang J, Zhang M, Sun B, Li Y, Xu P, Liu C, Liu L*, Liu XD*. Hyperammonemia enhances the function and expression of P-glycoprotein an Mrp2 at the blood-brain barrier through NF-kB. J Neurochem. 2014; 131: 791.
4. Li F, Zhang M, Xu dan, Liu C, Zhong ZY, Jia LL, Hu MY, Yang Y, Liu L, Liu XD*. Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. Acta Pharmacol Sin 2014; 35: 792.
5. XuD, Li F, Zhang M, Zhang J^, LiuC, Hu MY, Zhong ZY, Jia LL, Wang DW, Wu J, LiuL, LiuXD*. Decreased exposure of simvastatinand simvastatinacid in a rat model of type 2 diabetes. Acta Pharmacol Sin.2014;35:1215.
6. Liu C, Hu MY, Zhang M, Li F, Li J, Zhang J, Li Y, Guo HF, Xu P, Liu L*, Liu XD*. Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats. Metabolism. 2014; 3:1342.
7. Liu C, Zhang M, Hu MY, Guo HF, Li J, Yu YL, Jin S, Wang XT, Liu L*, Liu XD*. Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. J Endocrinol. 2013; 217:185.
8. Jin S, Wang XT, Liu L, Yao D, Liu C, Zhang M, Guo HF, Liu XD*. P-glycoprotein and multidrug resistance-associated protein 2 are oppositely altered in brain of rats with thioacetamide-induced acute liver failure. Liver Int. 2013; 33: 274.
9. Yu YL, Wang XT, Liu C, Yao D, Hu MY, Li J, Hu N, Liu L*, Liu XD*. Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicol Appl Pharmacol. 2013; 266: 375.
10. Guo H, Liu C, Li J, Zhang M, Hu M, Xu P, Liu L*, Liu XD*. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3Ainduction-mediated drug–drug interactions. J Pharm Sci. 2013; 102: 2819.
11.Wang J, Xia S, Weifang Xue Xue W, Wang D, Sai Y, Liu L, Liu XD*. A semi- physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Euro J Pharm Sci. 2013;50:290.
12. Liu HY, Liu L, Li J, Duan R, Hu N, Guo HF, Zhong ZY, Liu XD*. Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus. Drug Metab Dispos. 2012; 40: 1104.
13.YAO D, Liu L, Jin S, Li J, Liu XD*. Overexpression of multidrug resistance-associated protein 2 inthe brain of pentylenetetrazole-kindledrats. Neuroscience. 2012;227:283.
14. Liu L, Yu YL, Liu C, Wang XT, Liu XD*, Xie L. Insulin deficiency induces abnormal increase in intestinal disaccharidase activities and expression under diabetic states, evidences from in vivo and in vitro study. Biochem Pharmacol. 2011; 82: 1963.
15.Yao D, Yang ZH, Liu L, Li J, Yu YL, Zhang LL, Pan X, Liu XD*, Xie L, Wang GJ. Verapamil exerts biphasic modulation on phenobarbital transport across blood brain barrier, evidence from in vivo and in vitro study. N-S Arch Pharmacol2011；383：393.
16. Hu N, Xie S, Liu L, Wang X, Pan X, Chen G, Zhang L, Liu H, Liu X*, Liu X, Xie L, Wang G. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos. 2011; 39: 419.
17..Pan X, Wang P, Hu N, Liu L, Liu X*, Xie L, Wang G.A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline /antofloxacininteraction in both rats and humans. Drug Metab Pharmacokinet. 2011 ;26:387.
18.Jing X, Liu X, Wen T, Xie S, Yao D,Liu X*, Wang G, Xie L. Combined effect of epileptic seizure and drug induction resulted in overexpression of P-glycoprotein in brain of kindled rats. Brit J Pharmacol；Brit J Pharmacol. 2010;159;1511-22
19.Yu Y, Liu L, Wang X, Liu X, Liu X*, Xie L, Wang G. Modulation of glucagon-like peptide-1 release by berberine: In vivo and in vitro studies Biochem Pharmacol 2010; 79: 1000
20. Liu L, YL Yu, Y Li, YW Liu, Y Liang,XD Liu*, Xie L,Wang GJ. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. N-S Arch Pharmacol. 2010; 381:371.